Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Acad Dermatol ; 78(6): 1195-1204.e1, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29288099

ABSTRACT

BACKGROUND: Peristomal pyoderma gangrenosum (PPG) is an uncommon subtype of pyoderma gangrenosum. PPG is a challenging condition to diagnose and treat; no evidence-based guidelines exist. OBJECTIVE: We sought to identify important clinical features of PPG and effective treatments available for its management. METHODS: A systematic literature review of PPG was performed using PubMed, Medline, and Embase databases. RESULTS: We describe 335 patients with PPG from 79 studies. Clinical features include a painful, rapidly progressing ulcer with undermined, violaceous borders with a history of ostomy leakage and local skin irritation or trauma. Systemic steroids are first-line therapy; infliximab and adalimumab provide concomitant control of active inflammatory bowel disease. Combination local and systemic therapy was commonly used. Wound dressings, vehicle selection, and appropriate ostomy devices to minimize leakage, irritation, and pressure-induced ischemia can improve healing. Distinct from classic ulcerative pyoderma gangrenosum, surgical approaches, such as stoma closure and resection of active inflammatory bowel disease, have an effective role in PPG management. LIMITATIONS: PPG is a rare disease lacking randomized trials or diagnostic guidelines. Treatment duration and follow-up time among studies are variable. CONCLUSIONS: Key clinical characteristics of PPG are highlighted. Several treatments, including a more prominent role for surgical intervention, may be effective for PPG treatment.


Subject(s)
Enterostomy/adverse effects , Postoperative Complications/therapy , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/therapy , Skin Care/methods , Surgical Stomas/adverse effects , Adrenal Cortex Hormones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Biological Products/therapeutic use , Colitis, Ulcerative/surgery , Crohn Disease/surgery , Disease Management , Drug Therapy, Combination , Female , Humans , Male , Postoperative Complications/diagnosis , Prognosis , Pyoderma Gangrenosum/etiology , Reoperation/methods , Severity of Illness Index
2.
J Am Acad Dermatol ; 73(4): 691-8, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26253362

ABSTRACT

Pyoderma gangrenosum is a challenging skin condition to identify and treat because of its multifactorial pathogenesis. It is a rare cutaneous manifestation diagnosed clinically by exclusion of infection, neoplasia, thrombophilia, and other inflammatory conditions. Pathogenetic and treatment studies are scarce. Abnormalities in the function of inflammatory cytokines, the immune system, and neutrophils combined with specific genetic mutations predispose patients to develop this complex disease process. Early recognition of patients at risk for pyoderma gangrenosum, the necessity to improve its early diagnosis, and the future outlook of targeted and personalized therapies relies on the improved comprehension of the complex pathogenesis of pyoderma gangrenosum.


Subject(s)
Cytokines/metabolism , Genetic Testing , Immunosuppressive Agents/therapeutic use , Pyoderma Gangrenosum/physiopathology , Biopsy, Needle , Disease Progression , Early Diagnosis , Female , Humans , Immunohistochemistry , Male , Prognosis , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/genetics , Risk Assessment , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...